Browse the evidence

Semaglutide shows effective weight reduction and HbA1c lowering in Type 2 Diabetes treatment.

Semaglutide can be recommended for patients with Type 2 Diabetes who also need to lose weight.

Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes.

Healthcare providers may consider glucagon-like peptide-1 receptor agonists as a treatment option for obesity and diabetes risk reduction.

Treatment proposals for obesity must be individualized according to phenotyping.

Tailoring obesity treatment plans to individual profiles can enhance effectiveness.

Glucagon-like peptide-1 receptor agonists induce substantial and durable weight loss and improve obesity-related gastrointestinal outcomes.

Practitioners can consider GLP-1 receptor agonists as effective treatments for weight management and gastrointestinal health.

GLP-1 receptor agonists have shown remarkable weight loss potential comparable to bariatric interventions.

GLP-1 receptor agonists may be a viable non-invasive alternative for weight loss in some patients.

Tirzepatide offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists.

Practitioners may consider Tirzepatide as a more effective option for managing glycemic control and weight in patients with T2DM.

The weight loss program reduced insomnia symptoms by -17.1 ± 7.4 (p = 0.03; d = -0.30) compared to the waitlist control group.

Weight loss interventions may be beneficial for improving sleep quality in cancer survivors.

Semaglutide is endorsed for obesity treatment following its FDA approval for type 2 diabetes.

Health practitioners can consider semaglutide as a treatment option for obesity.

Lifestyle modifications are often the first-line intervention for improving hormonal imbalances and menstrual cycles in women with PCOS.

Clinicians should consider lifestyle modifications as a primary strategy in managing PCOS.

Tirzepatide 10 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 5.3% to 1.2%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Tirzepatide 15 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 4.9% to 1.0%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Two-thirds of respondents reported reduced appetite, food cravings, or body weight.

Practitioners can expect that a significant portion of patients may experience appetite reduction and weight loss with Ozempic.

Semaglutide (Wegovy) has demonstrated unprecedented efficacy in weight reduction, glycaemic control, and cardiovascular protection.

Semaglutide may be a highly effective treatment option for obesity and type 2 diabetes.

Subcutaneous semaglutide 0.5 mg and subcutaneous liraglutide 3 mg are effective treatments for reducing weight among people with obesity in a real-world scenario after 3 months.

Both semaglutide and liraglutide can be considered effective options for weight management in clinical practice.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide potent weight reduction among persons with overweight/obesity and show cardiovascular benefits.

GLP-1 RAs may be considered as a therapeutic option for weight management in patients with HIV and obesity.

Semaglutide is endorsed as a secondary treatment for improving glycemic control in type 2 diabetes mellitus (T2DM).

Practitioners can consider semaglutide as a secondary option for patients with T2DM to improve blood sugar control.

Semaglutide is being investigated for its potential in combating obesity.

Practitioners should stay informed about the potential use of semaglutide for obesity management.

Semaglutide can help regulate blood sugar levels and decrease long-term health complications related to diabetes.

Practitioners can use semaglutide to manage blood sugar levels and reduce diabetes-related complications.

SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.

Semaglutide may significantly lower the risk of cardiovascular events in at-risk populations.

Obesity is a significant modifiable risk factor for atrial fibrillation (AF).

Practitioners should focus on managing obesity to reduce the risk of AF.

GLP-1 agonists are approved for weight loss in addition to their original approval for type 2 diabetes.

Healthcare providers should consider GLP-1 agonists for patients needing weight loss support.

GLP-1-based therapies elicit a clinically significant reduction in body weight.

Practitioners can expect GLP-1 therapies to aid in weight loss for patients with type 2 diabetes or obesity.

Tirzepatide reduces appetite and aids in weight reduction management.

Tirzepatide may be effective for patients seeking weight loss.

Tirzepatide is the first dual receptor agonist incorporated into therapeutic recommendations for type 2 diabetes.

Tirzepatide should be considered as a treatment option for type 2 diabetes.